Informations:
Erreur:
ID
34770
Description
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT02288273
Lien
https://clinicaltrials.gov/show/NCT02288273
Mots-clés
Versions (1)
- 27/01/2019 27/01/2019 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
27 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Type 2 Diabetes NCT02288273
Eligibility Type 2 Diabetes NCT02288273
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes NCT02288273
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Diabetes Mellitus, Non-Insulin-Dependent | Metformin Dose Stable U/day
Item
type 2 diabetes mellitus (t2dm) treated with stable dose of metformin > or = to 1500mg/day as monotherapy for at least 8 weeks
boolean
C0011860 (UMLS CUI [1])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0456683 (UMLS CUI [2,4])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0456683 (UMLS CUI [2,4])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) 7% to 10% at screening
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) < or = to 45 kg/m2
boolean
C1305855 (UMLS CUI [1])
Hypoglycemic Agents | Exception Metformin | Exception Metformin Extended Release
Item
history of taking antihyperglycemic therapy other than metformin or metformin extended release (xr) during the 8 weeks prior to screening
boolean
C0020616 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C1707968 (UMLS CUI [3,3])
C1705847 (UMLS CUI [2,1])
C0025598 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C1707968 (UMLS CUI [3,3])
Dipeptidyl-Peptidase IV Inhibitors | Pramlintide
Item
history of taking a dipeptidyl peptidase-4 (dpp-4) inhibitor or pramlintide during 12 weeks prior to screening
boolean
C1827106 (UMLS CUI [1])
C0537551 (UMLS CUI [2])
C0537551 (UMLS CUI [2])
Steroids | Inhaled steroids | Steroids Intrapulmonary
Item
history of potent, inhaled or intrapulmonary steroids 3 months prior to screening or during the study
boolean
C0038317 (UMLS CUI [1])
C2065041 (UMLS CUI [2])
C0038317 (UMLS CUI [3,1])
C1522224 (UMLS CUI [3,2])
C2065041 (UMLS CUI [2])
C0038317 (UMLS CUI [3,1])
C1522224 (UMLS CUI [3,2])
Weight-Loss Agents Prescription | Weight-Loss Agents Over the counter
Item
history of prescription or over the counter weight loss medication during 3 months prior to screening
boolean
C0376606 (UMLS CUI [1,1])
C0033080 (UMLS CUI [1,2])
C0376606 (UMLS CUI [2,1])
C0013231 (UMLS CUI [2,2])
C0033080 (UMLS CUI [1,2])
C0376606 (UMLS CUI [2,1])
C0013231 (UMLS CUI [2,2])
Exposure to Exenatide | Exposure to GLP-1 Receptor Agonist
Item
previous exposure to exenatide or any glucagon-like peptide-1 (glp-1) receptor agonist during 6 months prior to screening
boolean
C0332157 (UMLS CUI [1,1])
C0167117 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C2917359 (UMLS CUI [2,2])
C0167117 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C2917359 (UMLS CUI [2,2])